Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort

Shabana Amanda Ali*, Osvaldo Espin-Garcia, Andy K. Wong, Pratibha Potla, Madison McIntyre, Starlee Lively, Igor Jurisica, Rajiv Gandhi and Mohit Kapoor

Abstract

Introduction: The objective of this study is to identify circulating microRNAs that distinguish fast-progressing radiographic knee osteoarthritis (OA) in the Osteoarthritis Initiative cohort by applying microRNA-sequencing.

Methods: Participants with Kellgren–Lawrence (KL) grade 0/1 at baseline were included (N=106). Fast-progressors were defined by an increase to KL 3/4 by 4-year follow-up (N=20), whereas slow-progressors showed an increase to KL 2/3/4 only at 8-year follow-up (N=35). Non-progressors remained at KL 0/1 by 8-year follow-up (N=51). MicroRNA-sequencing was performed on plasma collected at baseline and 4-year follow-up from the same participants. Negative binomial models were fitted to identify differentially expressed (DE) microRNAs. Penalized logistic regression (PLR) analyses were performed to select combinations of DE microRNAs that distinguished fast-progressors. Area under the receiver operating characteristic curves (AUC) were constructed to evaluate predictive ability.

Results: DE analyses revealed 48 microRNAs at baseline and 2 microRNAs at 4-year follow-up [false discovery rate (FDR) < 0.05] comparing fast-progressors with both slow-progressors and non-progressors. Among these were hsa-miR-320b, hsa-miR-320c, hsa-miR-320d, and hsa-miR-320e, which were predicted to target gene families, including members of the 14-3-3 gene family, involved in signal transduction. PLR models included miR-320 members as top predictors of fast-progressors and yielded AUC ranging from 82.6 to 91.9, representing good accuracy.

Conclusion: The miR-320 family is associated with fast-progressing radiographic knee OA and merits further investigation as potential biomarkers and mechanistic drivers of knee OA.

Keywords: epigenetics, knee OA progression, longitudinal, noncoding RNAs, phenotyping, prognostic biomarkers, sequencing

Introduction

Characterizing disease phenotypes remains an outstanding challenge for osteoarthritis (OA), particularly for early stages of disease and for rapid disease progression.1 Although biochemical (e.g. collagen breakdown products) and imaging (e.g. magnetic resonance imaging) biomarkers have been explored for OA, these markers typically become robust in established disease. The ability to identify patients with early-stage and fast-progressing OA would support investigation of disease mechanisms, delivery of preventive interventions, and recruitment to clinical trials, and therefore is essential to advance the field.
MicroRNAs have emerged as powerful candidate biomarkers for musculoskeletal diseases (e.g. osteoporosis)2–3 and are known to play important mechanistic roles in OA.4,5 These small, stable, noncoding RNA molecules can be comprehensively profiled in liquid biopsies using microRNA-sequencing.6 Sequencing offers advantages with respect to sensitive and specific detection of microRNAs, especially compared with previous techniques such as microarrays which are limited to semi-quantification of preselected microRNAs. Recent sequencing studies in blood identified differentially expressed microRNAs in OA versus controls and in early-stage versus late-stage radiographic knee OA.7–10 Among these, a well-powered study revealed a signature of seven circulating microRNAs to be associated with early-stage radiographic knee OA.8 However, sequencing remains to be applied to large-scale longitudinal cohorts to identify microRNAs that are associated with disease progression.

The purpose of this study is to apply our method for microRNA-sequencing6 to identify circulating microRNAs that are associated with radiographic knee OA progression. We hypothesize that unique microRNAs in plasma are associated with fast-progressing radiographic knee OA as compared with slow-progressing and non-progressing radiographic knee OA. To test this hypothesis, we leverage the Osteoarthritis Initiative (OAI) which is a well-characterized knee OA cohort with imaging, biospecimens, and clinical data available from baseline to 10-year follow-up, with ongoing collection.11 We apply a data-driven strategy to define groups that advance from early to late stages of radiographic knee OA, then perform microRNA-sequencing at both baseline and 4-year follow-up in the same participants to identify circulating microRNAs that are differentially expressed over time (Figure 1). These microRNAs may be clinically relevant as potential biomarkers and/or mechanistic drivers of disease.

Methods

OAI cohort

The OAI includes participants with varying disease trajectories that can be defined based on established features such as Kellgren–Lawrence (KL) radiographic grades for knee OA severity.12 From among the 1926 participants in the OAI with KL grades 0/1 at baseline, we used literature recommendations to guide our selection of a sample size of at least 20 participants per group which can reliably detect a 1.5-fold change in microRNA expression with a power of 80%.9 Based on individual KL-grade trajectories over 8 years, fast-progressors were defined as participants who increased to KL 3/4 by 4-year follow-up (N = 20). Slow-progressors were defined by KL 0/1 at baseline and 4-year follow-up, with KL 2/3/4 by 8-year follow-up (N = 35). Non-progressors remained at KL 0/1 throughout the 8-year follow-up and N = 51 were selected using propensity score methods. The OAI cohort is described in detail at https://nda.nih.gov/oai and has been approved by the Institutional Review Board for the University of California, San Francisco (FWA approval # 00000068; IRB approval # 10-00532), and its affiliates. The following OAI datasets were used: XRay[00-10], AllClinical[00-10], Kxr_sq_bu[00-10], Enrollees, Biomarkers[00-10], and Outcomes99. All participants provided written informed consent to the OAI.

MicroRNA-sequencing

Frozen aliquots of 200 µL plasma collected at baseline (N = 106) and 4-year follow-up (N = 102; 4 samples were not available from the OAI) were obtained from the OAI and stored at −80°C until use. After thawing on ice, RNA was isolated using the miRNeasy Serum/Plasma Advanced kit (QIAGEN, Hilden, Germany) and microRNA libraries were created with the QIAseq miRNA Library kit (QIAGEN, Hilden, Germany). This protocol is described in detail in our previous publication.8 Single-end 76-base sequencing on the Illumina NextSeq500 platform was performed to an average depth of 11.6 million (± 2.6 million standard deviation) reads per sample. Sequencing data were deposited in the Gene Expression Omnibus database under accession number GSE183188.

Bioinformatics

Quality control of sequencing data (e.g. Q score ≥ 30), reference-based alignment, counts generation, and novel microRNA discovery14 were performed as previously described.6,8 No samples were excluded from the present analysis due to insufficient data quality. For microRNAs shortlisted by differential expression (DE)
analyses, predicted target genes were retrieved from mirDIP version 4.1 (http://ophid.utoronto.ca/mirDIP).\textsuperscript{15} Pathway enrichment analysis was performed for each set of targets using pathDIP 4 API in R 4.0.3.\textsuperscript{16} From the pathways common among at least three of four lists, the gene-pathway links were further investigated. Protein interactions for the gene targets were retrieved from Integrative Interactions Database (IID), version 2021-05 (http://ophid.utoronto.ca/iid).\textsuperscript{17} The network was visualized using NAViGaTOR, version 3.0.16,\textsuperscript{18} and exported to Adobe Illustrator, version 26.0.2, to be finalized with legends.

**Statistical analysis**

DE analyses were performed at baseline and 4-year follow-up using negative binomial models cross-sectionally and a negative binomial mixed model longitudinally.\textsuperscript{19,20} A propensity score constructed using age, sex, body mass index (BMI), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)\textsuperscript{21} and arthroscopy status (whether the participant underwent arthroscopy prior or during the 8-year follow-up) was introduced in the models as a covariate; additionally, the cross-sectional models were adjusted for sequencing batch. MicroRNAs with false discovery rate (FDR) < 0.05 were considered in penalized logistic regression (PLR) models for each of the studied pairs (fast- versus slow-progressors, fast- versus non-progressors, and slow-versus non-progressors) to determine their predictive performance.\textsuperscript{22} PLR hyperparameters were tuned using threefold 50-repeated cross-validation with Cohen’s kappa as a performance metric.
measure under the ‘one-SE’ rule for model selection. Resulting microRNA-based models were benchmarked against clinicodemographics-only models using area under the receiver operating characteristic curve (AUC).

**Results**

**Characterizing participants by rate of radiographic knee OA progression**

Using a data-driven phenotyping approach, we characterized the rate of radiographic knee OA progression in 106 participants and identified three distinct groups (Figure 2(a)). By 4-year follow-up, fast-progressors exhibited KL 3/4 ($N = 20$), whereas slow-progressors remained at KL 0/1 and only exhibited KL 2/3/4 by 8-year follow-up ($N = 35$). Non-progressors remained at KL 0/1 through to 8-year follow-up ($N = 51$). Exploring clinicodemographic factors across groups, differences were found in worsening total WOMAC scores from baseline to 4-year follow-up and arthroscopy status (Table 1). More slow-progressors (42.9%) showed worsening WOMAC score compared with non-progressors (17.6%), despite both groups being KL 0/1 at 4-year follow-up. Furthermore, more fast-progressors and slow-progressors underwent arthroscopy as compared with non-progressors, suggesting that our definition of non-progressors was internally consistent.

**Identifying microRNAs associated with fast-progressing knee OA**

Following microRNA-sequencing, we identified 532 and 411 microRNAs at baseline and 4-year follow-up with greater than 10 counts-per-million in at least two samples among 106 and 102 samples, respectively. Cross-sectional DE analyses comparing the three groups pairwise within each time-point identified 78 microRNAs at baseline (Figure 2(b)) and 13 microRNAs at 4-year follow-up (Figure 2(c)) at FDR < 0.05 (Supplementary File 1). Among these, 48 microRNAs at baseline (Figure 2(d)) and 2 microRNAs at 4-year follow-up (Figure 2(e)) were upregulated when comparing fast-progressors versus slow-progressors and non-progressors, but not slow-progressors versus non-progressors. The two microRNAs at 4-year follow-up were hsa-miR-320c and hsa-miR-320d. Notably, hsa-miR-320d was also among the 48 microRNAs identified at baseline, along with hsa-miR-320b and hsa-miR-320e (Figure 3(a)). Therefore, hsa-miR-320d was significantly increased among fast-progressors as compared with both slow-progressors and non-progressors at both baseline and 4-year follow-up. Longitudinal DE analyses identified seven microRNAs between fast-progressors versus non-progressors (FDR < 0.05) and no significant differences between fast-progressors versus slow-progressors or slow-progressors versus non-progressors (Supplementary File 1). Our analysis for novel microRNAs identified four sequences at baseline and two at 4-year follow-up that were in >50% of fast-progressors, though the sequences were unique to each time-point (Supplementary Figure 1).

**Exploring the miR-320 family in fast-progressing knee OA**

To determine the extent to which the DE microRNAs could distinguish fast-progressors from slow-progressors and non-progressors, we built and tested a PLR model per group comparison. Using the comparison-specific DE microRNAs as input, we found that AUCs for the microRNA-based models were greater than those based on baseline age, sex, BMI, and WOMAC (Figure 3(b)). Of note, hsa-miR-320b/c/d/e were all among the top 20 predictors for the fast-progressor versus non-progressor model (Supplementary File 1). We then sought to predict the potential function of the miR-320 family. Bioinformatic analyses revealed that these miR-320 members had both unique and overlapping putative target genes and pathways, with 137 genes (Figure 4(a); Supplementary File 2) and 14 pathways (Figure 4(b); Supplementary File 3) common to miR-320b/c/d. Among these, four of the seven members of the 14-3-3 gene family comprising YWHAZ, YWHAQ, YWAHE, YWHAH, YWHAH, YWHAB, and SPN were identified to be annotated with eight common pathways each (Figure 4(c); Supplementary File 4). We further investigated the connection between the miR-320 family and the 14-3-3 gene family in mirDIP and found that all four members of the miR-320 family were predicted to target all seven members of the 14-3-3 gene family, albeit some predictions had lower confidence (Figure 4(d)). In addition, we found multiple protein–protein interactions connecting all seven members of the 14-3-3 gene family (Figure 4(d)).
Leveraging the OAI cohort, we used a data-driven approach to characterize three distinct disease progression groups that provide greater phenotypic resolution than dividing participants into radiographic progressors versus non-progressors alone. Applying microRNA-sequencing to samples from 106 participants at 2 time-points, we identified circulating microRNAs that are associated with fast-progressing radiographic knee OA.
over time, including members of the miR-320 family, which are predicted to target members of the 14–3–3 gene family among other genes. While future studies are required to externally validate these findings in independent longitudinal knee OA cohorts, our data suggest microRNAs may be key molecular markers and mechanistic drivers of fast-progressing knee OA.

Imaging and biochemical markers have been explored as prognostic biomarkers in the OAI cohort, yet are not currently in clinical use. As these approaches require structural changes to have occurred before markers can be detected, opportunities for prevention are reduced. As epigenetic regulators of gene expression, microRNAs may appear earlier in disease pathogenesis and therefore could precede irreversible structural damage in knee OA. This is a strength of microRNAs as biomarkers, and our data suggest unique combinations of microRNAs offer strong predictive ability. Through use of the OAI cohort, our microRNA-sequencing data can be integrated with other imaging and biochemical data to support discovery of composite biomarkers for OA.

To note limitations of this study, we characterized OA based on radiographic severity (i.e. KL grade) alone. Future studies may explore other structural (e.g. joint space narrowing) or symptomatic (e.g. pain) features that typify knee OA. We also selected a subset of the OAI cohort enriched for participants who progressed from early-stage radiographic knee OA at baseline (KL 0/1) to late-stage radiographic knee OA by 8-year follow-up (KL 3/4). Future studies with larger sample sizes could investigate broader and alternative definitions of fast-progressing knee OA (e.g. KL 2 to KL 4 in 4 years) while accounting for confounders such as comorbidities.

### Table 1. Clinicodemographic characteristics of progression groups.

|                | Non  | Slow | Fast | p-value |
|----------------|------|------|------|---------|
| Age, mean years (SD) | 59.2 (9.2) | 57.5 (8.4) | 61.0 (8.1) | 0.374 |
| Age, N [% > 60 years] | 20 (39.2) | 10 (28.6) | 11 (55.0) | 0.153 |
| Sex, N [% males] | 13 (25.5) | 9 (25.7) | 7 (35.0) | 0.696 |
| Race, N [% non-white] | 8 (15.7) | 2 (5.7) | 4 (20.0) | 0.247 |
| BMI, mean kg/m² (SD) | 28.8 (4.1) | 29.2 (5.1) | 28.5 (5.1) | 0.855 |
| **BMI categories:** |       |      |      | 0.513 |
| • Healthy weight = 18.5–24.9 kg/m², N [%] | 10 (19.6) | 7 (20.0) | 5 (25.0) |       |
| • Overweight = 25–29.9 kg/m², N [%] | 26 (51.0) | 12 (34.3) | 9 (45.0) |       |
| • Obese = 30+ kg/m², N [%] | 15 (29.4) | 16 (45.7) | 6 (30.0) |       |
| WOMAC worsening*, N [% worsen] | 9 (17.6) | 15 (42.9) | 6 (30.0) | 0.038* |
| Arthroscopy, N [% yes] | 3 (5.9) | 12 (34.3) | 6 (30.0) | 0.002* |
| Propensity score, mean (SD) | 0.43 (0.15) | 0.64 (0.22) | 0.55 (0.25) | <0.001* |

Each factor was summarized across progression groups by their means (standard deviations) or counts (proportions) for continuous or categorical factors, respectively. Differences among groups were ascertained using Welch (continuous) and chi-square (categorical) tests.

BMI, body mass index; SD, standard deviation; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

*Total WOMAC score with worsening defined by an increase of 7 or more points from baseline to 4-year follow-up.

*Statistically significant.
Figure 3. MiR-320 family members are distinguishing factors of fast-progressing knee OA. (a) Log2 fold changes for members of the miR-320 family identified as differentially expressed at FDR < 0.05 in at least one comparison at baseline and 4-year follow-up. (b) ROC curves comparing models using baseline clinicodemographic variables alone (orange) including age (continuous), sex, BMI (continuous), and WOMAC (continuous) against microRNA-based models (green) from each comparison. NS, not significant.

We report four of the five members of the miR-320 family to be associated with fast-progressing radiographic knee OA, a family of microRNAs our predictions show to have both unique and overlapping gene targets. Previous studies suggest miR-320a and miR-320c protect against OA cartilage degeneration, potentially through downregulation of the Wnt signaling pathway. In addition, plasma miR-320a along with miR-98-5p was found to distinguish between neuropathic and nociceptive musculoskeletal pain. Our data indicate miR-320d is upregulated in fast-progressors versus both slow-progressors and non-progressors at both baseline and 4-year follow-up, suggesting it is associated with fast-progressing knee OA over time and may have mechanistic functions through regulation of its targets, including the 14-3-3 gene family.

The 14-3-3 gene family comprises seven conserved protein isoforms which function to regulate signal transduction. Members of this family have been explored as biomarkers and mechanistic drivers of rheumatoid arthritis (RA) and OA. Of the seven isoforms, YWHAH and YWHAG were detected in synovial fluid from inflammatory joint disease patients, and YWHAH was elevated in the serum compared with healthy controls. Furthermore, YWHAH was found to correlate with other biomarkers of RA, and like YWHAE could induce inflammatory factors and signaling pathways linked to joint damage. Given the observed upregulation of miR-320 family members in fast-progressing radiographic knee OA, members of the 14-3-3 gene family would likely be downregulated in a direct regulatory relationship. Taken together, our data suggest nuanced interactions among individual miR-320 and 14-3-3 family members may be a mechanism for fine-tuning signal transduction, a hypothesis that merits further investigation for its potential role in fast-progressing knee OA.
Figure 4. MiR-320 family members are potential mechanistic players in fast-progressing knee OA. (a) Unique and overlapping mirDIP gene targets for four members of the miR-320 family, filtered for top 1%. (b) Unique and overlapping pathways for four members of the miR-320 family, filtered for $p < 0.01$. (c) Number of common enriched pathways (x-axis) with which the gene targets (y-axis) are annotated. (d) Predicted targeting of the 14-3-3 gene family by the miR-320 family using all mirDIP results. Edges with arrows denote the score class with V = very high, H = high, M = medium, and L = low according to the legend. Blue edges denote protein–protein interactions (PPIs) from IID.

Author contributions
Shabana Amanda Ali: Conceptualization; Writing – original draft.
Osvaldo Espin-Garcia: Formal analysis; Writing – original draft.
Andy K. Wong: Formal analysis; Writing – review & editing.
Pratibha Potla: Formal analysis; Writing – review & editing.
Chiara Pastrello: Formal analysis; Writing – review & editing.
Madison McIntyre: Methodology; Writing – review & editing.

Starlee Lively: Methodology; Writing – review & editing.
Igor Jurisica: Formal analysis; Writing – review & editing.
Rajiv Gandhi: Investigation; Writing – review & editing.
Mohit Kapoor: Conceptualization; Writing – review & editing

Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.A.A. and M.K. declare that they have filed a US
Provisional Patent Application no. 63/033,463 titled ‘Circulating MicroRNAs in Knee Osteoarthritis and Uses Thereof’. All other authors declare no conflict of interest.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is in part supported by grants to M.K. by the Canadian Institute of Health Research (#156299), the Krembil Foundation, and Schroeder Arthritis Institute via the University Health Network Foundation. Computational analyses were supported in part by funding from Natural Sciences Research Council (NSERC #203475), Canada Foundation for Innovation (CFI #225404, #30865), Ontario Research Fund (RDI #34876), IBM and Ian Lawson van Toch Fund to I.J. M.K. is the recipient of the Tier 1 Canada Research Chair and Tony and Shari Fell Platinum Chair in Arthritis Research. S.A.A. received the Arthritis Society postdoctoral fellowship. A.K.W. is supported by an Arthritis Society salary award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**ORCID iD**

Shabana Amanda Ali  
https://orcid.org/0000-0002-4339-9467

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Mobasheri A, Kapoor M, Ali SA, et al. The future of deep phenotyping in osteoarthritis: how can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease? *Osteoarthr Cartil Open* 2021; 3: 100144.

2. Wang Z, Lu Y and Han J. Peripheral blood microRNAs: a novel tool for diagnosing disease? *Intractable Rare Dis Res* 2012; 1: 98–102.

3. Grillari J, Makitie RE, Kocijan R, et al. Circulating miRNAs in bone health and disease. *Bone* 2021; 145: 115787.

4. Endisha H, Rockel J, Jurisica I, et al. The complex landscape of microRNAs in articular cartilage: biology, pathology, and therapeutic targets. *JCI Insight* 2018; 3: e121630.

5. Ali SA, Peffers MJ, Ormseth MJ, et al. The non-coding RNA interactome in joint health and disease. *Nat Rev Rheumatol* 2021; 17: 692–705.

6. Potla P, Ali SA and Kapoor M. A bioinformatics approach to microRNA-sequencing analysis. *Osteoarthr Cartil Open* 2021; 3: 100131.

7. Rousseau JC, Millet M, Croset M, et al. Association of circulating microRNAs with prevalent and incident knee osteoarthritis in women: the OFELY study. *Arthritis Res Ther* 2020; 22: 2.

8. Ali SA, Gandhi R, Potla P, et al. Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee osteoarthritis. *Osteoarthritis Cartilage* 2020; 28: 1471–1481.

9. Ramos YFM, Coutinho de Almeida R, Lakenberg N, et al. Circulating microRNAs highly correlate to expression of cartilage genes potentially reflecting OA susceptibility-towards identification of applicable early OA biomarkers. *Biomolecules* 2021; 11: 1356.

10. Jiang Y, Shen Y, Ding L, et al. Identification of transcription factors and construction of a novel miRNA regulatory network in primary osteoarthritis by integrated analysis. *BMC Musculoskelet Disord* 2021; 22: 1008.

11. Eckstein F, Kwoh CK, Link TM, et al. Imaging research results from the osteoarthritis initiative (OAI): a review and lessons learned 10 years after start of enrolment. *Ann Rheum Dis* 2014; 73: 1289–1300.

12. Kellgren JH and Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis* 1957; 16: 494–502.

13. Kok MGM, de Ronde MWJ, Moerland PD, et al. Small sample sizes in high-throughput miRNA screens: a common pitfall for the identification of miRNA biomarkers. *Biomol Detect Quantif* 2018; 15: 1–5.

14. Friedlander MR, Mackowiak SD, Li N, et al. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. *Nucleic Acids Res* 2012; 40: 37–52.

15. Tokar T, Pastrello C and Rossos AEM, et al. mirDIP 4.1-integrative database of human microRNA target predictions. *Nucleic Acids Res* 2018; 46: D360–D370.

16. Rahmati S, Abovsky M, Pastrello C, et al. PathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. *Nucleic Acids Res* 2020; 48: D479–D488.
17. Kotlyar M, Pastrello C, Ahmed Z, et al. IID 2021: towards context-specific protein interaction analyses by increased coverage, enhanced annotation and enrichment analysis. **Nucleic Acids Res** 2022; 50: D640–D647.

18. Brown KR, Otasek D, Ali M, et al. NAViGaTOR: network analysis, visualization and graphing Toronto. **Bioinformatics** 2009; 25: 3327–3329.

19. Anders S and Huber W. Differential expression analysis for sequence count data. **Genome Biol** 2010; 11: R106.

20. Zhang X and Yi N. NBZIMM: negative binomial and zero-inflated mixed models, with application to microbiome/metagenomics data analysis. **BMC Bioinformatics** 2020; 21: 488.

21. Angst F, Aeschlimann A and Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. **Arthritis Rheum** 2001; 45: 384–391.

22. Friedman J, Hastie T and Tibshirani R. Regularization paths for generalized linear models via coordinate descent. **J Stat Softw** 2010; 33: 1–22.

23. Kraus VB, Collins JE, Hargrove D, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. **Ann Rheum Dis** 2017; 76: 186–195.

24. Collins JE, Losina E, Nevitt MC, et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. **Arthritis Rheumatol** 2016; 68: 2422–2431.

25. Liang Y, Li S and Tang L. MicroRNA 320, an anti-oncogene target miRNA for cancer therapy. **Biomedicines** 2021; 9: 591.

26. Peng H, Liang D, Li B, et al. MicroRNA-320a protects against osteoarthritis cartilage degeneration by regulating the expressions of BMI-1 and RUNX2 in chondrocytes. **Pharmazie** 2017; 72: 223–226.

27. Hu S, Mao G, Zhang Z, et al. MicroRNA–320c inhibits development of osteoarthritis through downregulation of canonical Wnt signaling pathway. **Life Sci** 2019; 228: 242–250.

28. Meng F, Zhang Z, Chen W, et al. MicroRNA-320 regulates matrix metalloproteinase-13 expression in chondrogenesis and interleukin-1beta-induced chondrocyte responses. **Osteoarthritis Cartilage** 2016; 24: 932–941.

29. Zhang X, Sun C, Yu HC, et al. Targeted inhibition of beta-catenin by miR-320 and decreased MMP-13 expression in suppressing chondrocyte collagen degradation. **Eur Rev Med Pharmacol Sci** 2018; 22: 5828–5835.

30. Dayer CF, Luthi F, Le Carre J, et al. Differences in the miRNA signatures of chronic musculoskeletal pain patients from neuropathic or nociceptive origins. **PLoS ONE** 2019; 14: e0219311.

31. Fu H, Subramanian RR and Masters SC. 14-3-3 proteins: structure, function, and regulation. **Annu Rev Pharmacol Toxicol** 2000; 40: 617–647.

32. Maksymowych WP and Marotta A. 14-3-3eta: a novel biomarker platform for rheumatoid arthritis. **Clin Exp Rheumatol** 2014; 32: S-35–S-39.

33. Fu W, Hettinghouse A, Chen Y, et al. 14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis. **Ann Rheum Dis** 2021; 80: 1615–1627.

34. Kilani RT, Maksymowych WP, Aitken A, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. **J Rheumatol** 2007; 34: 1650–1657.

35. Guan SZ, Yang YQ, Bai X, et al. Serum 14-3-3eta could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity. **Ann Clin Lab Sci** 2019; 49: 57–62.

36. Maksymowych WP, van der Heijde D, Allaart CF, et al. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. **Arthritis Res Ther** 2014; 16: R99.

37. Millerand M, Sudre L, Nefta M, et al. Activation of innate immunity by 14-3-3 epsilon, a new potential alarmin in osteoarthritis. **Osteoarthritis Cartilage** 2020; 28: 646–657.